[1] Article Title: Prevalence in congenital myasthenic syndrome
	•	Line(s): Title line at top of page
	•	Section: Title/Header
	•	Quote(s): “Prevalence in congenital myasthenic syndrome”

⸻

[2] Publication Year: 2020
	•	Line(s): Footer reference and citation info
	•	Section: Footer / Metadata
	•	Quote(s): “Volume 26, P5-6, May 2020”

⸻

[3] Region: Global
	•	Line(s): Paragraph 2
	•	Section: Main Text
	•	Quote(s): “The prevalence of CMS varies considerably between regions.” (Followed by UK, Brazil, and general estimate)

⸻

[4] Country: United Kingdom, Brazil
	•	Line(s): Paragraph 2
	•	Section: Main Text
	•	Quote(s): “In a UK-based study… In a Brazilian study…”

⸻

[5] Coverage Area: International
	•	Line(s): Throughout
	•	Section: Main Text
	•	Quote(s): Multiple prevalence estimates across countries are discussed.

⸻

[6] Study Design: Commentary (not a primary study)
	•	Line(s): Entire document
	•	Section: Entire article
	•	Quote(s): This is an editorial commentary rather than a formal research study.

⸻

[7] Study Population: Patients with congenital myasthenic syndromes (CMS)
	•	Line(s): Paragraph 1
	•	Section: Main Text
	•	Quote(s): “Congenital myasthenic syndromes (CMS) constitute a group of… neuromuscular transmission disorders”

⸻

[8] Population Characteristics: NR
	•	Line(s): Paragraph 1
	•	Section: Main Text
	•	Quote(s): “mostly early-onset… increased fatigability… permanent weakness… cognitive impairment, dysmorphism, neuropathy, or epilepsy…”

⸻

[9] Data Source Type: Multiple secondary sources (literature-based)
	•	Line(s): Paragraph 2
	•	Section: Main Text
	•	Quote(s): “In a UK-based study… In a Brazilian study… In a recent review…”

⸻

[10] Data Source Details: Previously published studies (UK prevalence, Brazilian prevalence, review-based estimates)
	•	Line(s): Paragraph 2
	•	Section: Main Text
	•	Quote(s): “In a UK-based study the prevalence varied… In a Brazilian study… In a recent review…”

⸻

[11] Study Timeline Type: NR
	•	Line(s): NR
	•	Section: Not applicable
	•	Quote(s): NR

⸻

[12] Number of Sites: NR
	•	Line(s): NR
	•	Section: Not applicable
	•	Quote(s): NR

⸻

[13] Study Start Year: NR
	•	Line(s): NR
	•	Section: Not applicable
	•	Quote(s): NR

⸻

[14] Study End Year: NR
	•	Line(s): NR
	•	Section: Not applicable
	•	Quote(s): NR

⸻

[15] Main Ethnicity: NR
	•	Line(s): NR
	•	Section: Not specified
	•	Quote(s): NR

⸻

[16] Ethnicity Details: NR
	•	Line(s): NR
	•	Section: Not specified
	•	Quote(s): NR

⸻

[17] Disease Studied: Congenital myasthenic syndromes (CMS), subtypes mentioned
	•	Line(s): Paragraphs 1 and 2
	•	Section: Main Text
	•	Quote(s): “CMS are categorized as pre-synaptic… post-synaptic… glycosylation defects…”

⸻

[18] Diagnosis Method: NA
	•	Line(s): Last paragraph
	•	Section: Main Text
	•	Quote(s): “CMS is diagnosed upon the individual and family history… and upon next generation sequencing (NGS)”

⸻

[19] Diagnosis Criteria Details: NA
	•	Line(s): Last paragraph
	•	Section: Main Text
	•	Quote(s): “clinical exam, low- and high-frequency repetitive nerve stimulation… absence of antibodies… next generation sequencing (NGS)”

⸻

[20] Disease Phase: NA
	•	Line(s): Paragraph 1
	•	Section: Main Text
	•	Quote(s): “Clinical severity varies considerably… mild, transient weakness and permanent weakness”

⸻

[21] Cohort Age Group: NR
	•	Line(s): Paragraph 1
	•	Section: Main Text
	•	Quote(s): “mostly early-onset… pediatric population…”

⸻

[22] Female % in Cohort: NR
	•	Line(s): NR
	•	Section: Not specified
	•	Quote(s): NR

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: Not specified
	•	Quote(s): NR